Clinical trial
Post-marketing Surveillance to Assess the Safety and Effectiveness of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the "Standard for Re-examination of New Drugs"
NCT03740230 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-marketing Surveillance to Assess the Safety and Effectiveness of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the "Standard for Re-examination of New Drugs"
- Lead sponsor
- AbbVie
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 26, 2018
- Completion date
- July 21, 2023
- Enrollment
- 3,134 (actual)
- Sites
- 61
Conditions
As the registry lists them; a condition with its own page is linked.